This weekend, CRISPR Therapeutics shared positive initial data from the Phase I COBALT-LYM trial of CTX130, an allogeneic CAR-T cell therapy, which demonstrated safety and efficacy when used to target solid tumors and certain hematological malignancies expressing CD70. 

Last month, Seattle Genetics scored an ultrafast FDA nod for Adcetris in patients with newly diagnosed peripheral T-cell lymphoma, and data presented at the American Society of Hematology annual meeting show why.

• PTCL accounts for approximately 10 percent of non-Hodgkin lymphoma cases in the U.S. and Europe
• It may account for as much as 24 percent in parts of Asia.

• Results from the trial demonstrated that combination treatment with Adcetris plus CHP was superior to the control arm for progression free survival (PFS)
• All other key secondary endpoints were met
•  A recent small study indicated that Adcetris used combination with other treatments may increase lung toxicity in children and young adults.
• Adcetris generated approximately $640 million in 2017